Publication | Closed Access

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Medicinal ChemistryUrologyMedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentProstatic DiseaseAntitumour ActivityOncologyDrug Discovery